Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRP2 peptide-pulsed dendritic cells
- Development stage
- Unknown
- Lead developer
- University of California, Los Angeles
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous, Intravenous
01
Overview
TRP2 peptide-pulsed dendritic cells are an autologous cellular immunotherapy designed to treat melanoma and other TRP2-expressing malignancies. The therapeutic process involves isolating a patient's monocytes, differentiating them into dendritic cells (DCs) ex vivo, and loading (pulsing) them with peptides derived from Tyrosinase-related protein 2 (TRP2), also known as L-dopachrome tautomerase. TRP2 is a melanocyte-specific enzyme that is highly conserved and frequently overexpressed in melanoma cells, making it a viable tumor-associated antigen. Once matured and antigen-loaded, these DCs are re-administered to the patient, where they migrate to secondary lymphoid organs to present TRP2 epitopes to naive T cells. This interaction triggers the activation and expansion of TRP2-specific CD8+ cytotoxic T lymphocytes (CTLs), which are then capable of recognizing and lysing tumor cells that express the TRP2 antigen. This approach leverages the potent antigen-presenting capacity of dendritic cells to overcome immune tolerance and generate a targeted anti-tumor response.
- Other names
- TRP-2-pulsed dendritic cell vaccineTRP2-pulsed dendritic cell vaccineTRP 2-pulsed dendritic cell vaccineTyrosinase-related protein 2-pulsed dendritic cellsTRP2-pulsed DC vaccineTRP-2-pulsed DC vaccineTRP 2-pulsed DC vaccine
02
Targets
TYRP2 (Tyrosinase-related Protein 2)Tyrosinase-related protein 2-specific T cell receptor (TRP2-specific TCR)
Beyond the preview
Go deeper on TRP2 peptide-pulsed dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRP2 peptide-pulsed dendritic cells.